# Analysis of Influences of Sjögren’s Disease and Anti-Ro/SS-A Antibodies on Clinical Course of Patients with Rheumatoid Arthritis Complicated by Lymphoproliferative Disorders: A Pilot Study

**Authors:** Yoshiro Horai, Shota Kurushima, Hideki Nakamura, Atsushi Kawakami

PMC · DOI: 10.3390/jcm15062271 · 2026-03-17

## TL;DR

This study explores whether Sjögren’s disease and anti-Ro/SS-A antibodies influence the progression of rheumatoid arthritis complicated by lymphoproliferative disorders.

## Contribution

A novel pilot study analyzing the potential link between Sjögren’s disease, anti-Ro/SS-A antibodies, and lymphoproliferative disorders in rheumatoid arthritis patients.

## Key findings

- Three out of 25 RA patients were diagnosed with Sjögren’s disease based on clinical and antibody criteria.
- Mucosa-associated lymphoid tissue lymphoma was found in only one patient who was anti-Ro/SS-A positive but not diagnosed with Sjögren’s disease.
- No significant differences were found in clinical characteristics or disease intervals between anti-Ro/SS-A positive and negative patients.

## Abstract

Background/Objectives: Lymphoproliferative disorders (LPDs) are adverse effects of methotrexate (MTX) prescribed for rheumatoid arthritis (RA). Sjögren’s disease (SjD), for which the presence of anti-Ro/SS-A antibodies (Abs) is a diagnostic criterion, might accompany RA and be a risk factor for LPDs. We conducted a retrospective study to analyze the effects of SjD or anti-Ro/SS-A Ab positivity on the clinical course of patients with RA complicated by LPDs. Methods: We retrospectively analyzed 25 patients in our department who had RA complicated by LPDs, specifically collecting clinical information regarding the complications of SjD and positivity for anti-Ro/SS-A Abs. Results: In total, 25 patients with RA were included in this study, 3 of which were diagnosed with SjD by attending physicians based on sicca symptoms and positiveness of anti-Ro/SS-A antibodies. No significant differences in clinical characteristics except for SjD diagnosis given by attending physicians were found between the patients positive for anti-Ro/SS-A Abs and the patients negative for anti-Ro/SS-A Ab. The most common histologic LPD subtype was diffuse large B cell lymphoma, while mucosa-associated lymphoid tissue lymphoma, the histologic subtype often diagnosed as SjD-LPD, was found in only one patient, who was positive for anti-Ro/SS-A Abs without an SjD diagnosis. There were no significant differences in the intervals between the RA and LPD diagnoses and those of SjD and anti-Ro/SS-A Ab positivity. Conclusions: While the rate of anti-Ro/SS-A Ab positivity in the study population seemed to be higher than that in the general RA population, any potential effects of SjD on RA-LPD development were not ascertained in this study.

## Linked entities

- **Chemicals:** methotrexate (PubChem CID 4112)
- **Diseases:** rheumatoid arthritis (MONDO:0008383), diffuse large B cell lymphoma (MONDO:0018905), mucosa-associated lymphoid tissue lymphoma (MONDO:0007650)

## Full-text entities

- **Genes:** TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}
- **Diseases:** SjD (MESH:D012859), mucosa-associated lymphoid tissue lymphoma (MESH:D018442), LPDs (MESH:D008232), large B cell lymphoma (MESH:D016393), RA (MESH:D001172)
- **Chemicals:** MTX (MESH:D008727)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13027020/full.md

---
Source: https://tomesphere.com/paper/PMC13027020